Claudia D. Baldus

Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

Susan P. Whitman, Kellie J. Archer, Feng Lin et al. · PubMed · 2001 · 638 citations

Hematological Malignancy, Flt3 Gene, Medicine +13

MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia

Guido Marcucci, Michael D. Radmacher, Kati Maharry et al. · New England Journal of Medicine · 2008 · 437 citations · Full text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, <i>CEBPA</i> Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Michael D. Radmacher et al. · Journal of Clinical Oncology · 2008 · 303 citations · Full text